Paratus ClinicalParatus Clinical
  • About
    • Team
    • Training
    • Capability
    • Recruitment
    • Quality
    • Vision, Mission & Values
  • Locations
    • New South Wales
    • Victoria
    • Queensland
    • Australian Capital Territory
    • New Zealand
  • Register
    • Vaccine Trials
    • Weight Loss Trials
    • Cardiovascular Trials
    • Respiratory Trials
    • Dermatology Trials
    • Mental Health Trials
    • Diabetes Trials
    • Renal Trials
  • Trials
    • Case Studies
    • All Trials
  • Resources
    • What is a Clinical Trial?
    • Articles
    • News
    • Refer a Friend
  • Contact
Investigational Study for Relapse Prevention in Adults Living with Depression Investigational Study for Relapse Prevention in Adults Living with Depression

Investigational Study for Relapse Prevention in Adults Living with Depression

Study Information:

This clinical research study is exploring an investigational treatment used alongside usual care for adults living with depression.

Depression is a condition that can change over time. While many people respond well to treatment, it’s common for symptoms to return after a period of feeling better.

Researchers are looking at whether a once‑weekly injectable treatment, when added to existing prescribed treatment, may help delay the return of symptoms and support people in maintaining their wellbeing over time.

Who is it for?

You may be eligible if you:

  • Are aged 18 to 75 years
  • Have been diagnosed with depression
  • Are currently feeling well or have only mild symptoms
  • Are receiving stable prescribed treatment
  • Are willing to continue your current treatment during the study
  • Are able to attend study visits and complete assessments
  • Are willing to self‑administer a weekly injection

What does study participation look like?

If you are eligible, participation in this study will begin with a screening period of approximately 4 weeks to confirm whether the study is suitable for you.

Following screening, participants will enter the treatment phase and remain in the study until certain study criteria are met. The overall length of participation may vary between individuals.

Participants will be randomly assigned to receive either the investigational treatment or a placebo (inactive treatment). Neither you nor the study team will know which treatment you are receiving during the study. The study treatment is self‑administered as a once‑weekly injection under the skin. You will attend regular clinic visits, approximately every 4 weeks, where the study team will carry out assessments and provide ongoing support. These visits may include questionnaires, health checks, and other routine assessments. Throughout the study, researchers will monitor your mood, day‑to‑day functioning, overall health, and safety. Clinic visits will take place during business hours of 9am–5pm, Monday–Friday.

All study‑related care is provided at no cost, and eligible participants will be reimbursed for their time and travel.